In conclusion, our study, conducted through in vitro and in vivo experiments, underscores the potential of AB23A in ameliorating hepatic steatosis, likely via GRP94 inhibition, consequently impeding ERS and ERAD processes while restoring ER equilibrium (Figure 7). The gene discussed is HSP90B1; the disease is fatty liver disease.